Advantages of ebastine in the treatment of chronic urticaria

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Chronic urticaria (CU) is a condition caused by known and unknown causes, characterized by the appearance of wheals or angioedemas, each lasting no more than 24 hours, daily or almost daily for more than 6 weeks. Most cases of CU include chronic spontaneous urticaria (CSU), which has no apparent external cause and occurs without any specific external trigger, while induced urticaria (CIU) is caused by a specific external stimulus. In one-third of patients, the disease may occur in a combined form of CSU and CIU Combined forms of urticaria (CSU+CIU) are a condition characterized by a more severe course and treatment resistance. Comorbid associations of several CIU have been described, but large-scale studies of the prevalence and evaluation of treatment efficacy for such combinations have not been conducted. Ebastine is an antihistamine suitable for use in urticaria. The study was aimed to demonstrate the efficacy of ebastine in patients with various types of urticaria. In the treatment of CSU, the drug demonstrates high clinical efficacy at standard doses. This article demonstrates the efficacy of ebastine in various urticaria phenotypes, including comorbid CSU and CIU. The efficacy and reliable safety profile of standard doses of ebastine in the treatment of CSU, and in more complex cases (combined forms of urticaria) – escalated cases—provides disease control, which allows ebastine to be recommended as the drug of choice.

About the authors

Ekaterina A. Orlova

Penza Institute for Advanced Medical Training – Branch of the Russian Medical Academy of Postgraduate Education; Penza State University

Author for correspondence.
Email: lisaorl@yandex.ru
ORCID iD: 0000-0002-3902-2018

Dr. Sci. (Med.), Associate Professor, Head of the Department of Allergology and Immunology with a Course in Dermatovenereology and Cosmetology, Professor, Department of General and Clinical Pharmacology

Russian Federation, Penza; Penza

Julia A. Kandrashkina

Penza Institute for Advanced Medical Training – Branch of the Russian Medical Academy of Postgraduate Education; Penza State University

Email: novikova10l@mail.ru
ORCID iD: 0000-0002-5537-5729

Cand. Sci. (Med.), Associate Professor, Department of Allergology and Immunology with a Course in Dermatovenereology and Cosmetology, Associate Professor, Department of Obstetrics and Gynecology

Russian Federation, Penza; Penza

Elena M. Kostina

Penza Institute for Advanced Medical Training – Branch of the Russian Medical Academy of Postgraduate Education

Email: elmihkostina@yandex.ru
ORCID iD: 0000-0003-1797-8040

Dr. Sci. (Med.), Associate Professor, Professor, Department of Allergology and Immunology with a Course in Dermatovenereology and Cosmetology

Russian Federation, Penza

Maria N. Vikhreva

Penza Institute for Advanced Medical Training – Branch of the Russian Medical Academy of Postgraduate Education

Email: vichreva.87@mail.ru
ORCID iD: 0009-0002-7977-5441

Assistant Professor, Department of Allergology and Immunology with a Course in Dermatovenereology and Cosmetology

Russian Federation, Penza

References

  1. Клинические рекомендации РФ «Крапивница». Российская ассоциация аллергологов и клинических иммунологов. Общероссийская общественная организация «Российское общество дерматовенерологов и косметологов». Союз педиатров России. 2023 г. 99 с. [Clinical guidelines of the Russian Federation «Urticaria.»Russian Association of Allergists and Clinical Immunologists. All-Russian public organization «Russian Society of Dermatovenerologists and Cosmetologists. «Union of Pediatricians of Russia. 2023. 99 p. (In Russ)]
  2. Sadowska B., Gawinowska M., Sztormowska M., Chełmińska M. Hypersensitivity of azo dyes in urticaria patients based on a single-blind,placebo-controlled oral challenge. Postepy Dermatol Alergol. 2022;39(5):877–879. https://doi.org/10.5114/ada.2021.110263
  3. Fricke J., Ávila G., Keller T., et al. Prevalence of chronic urticaria in children and adults across the globe: Systematic review with meta-analysis. Allergy. 2020;75(2):423–432. https://doi.org/10.1111/all.14037
  4. Gonçalo M., Gimenéz-Arnau A., Al-Ahmad M., et al. The global burden of chronic urticaria for the patient and society. Br J Dermatol. 2021;184(2):226–236. https://doi.org/10.1111/bjd.19561
  5. Zuberbier T., Aberer W., Asero R., et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393–1414. https://doi.org/10.1111/all.13397
  6. Рубцова Л.А., Круглова Л.С., Круглова М.С. Хроническая спонтанная крапивница: высокие дозы и длительное применение неседативных антигистаминных препаратов второго поколения. Кремлевская медицина. 2022;(2):74–86. [Rubcova L.A., Kruglova L.S., Kruglova M.S. Chronic spontaneous urticaria: high doses and long-term use of second-generation non-sedating antihistamines. Kremlevskaya medicina. 2022;(2):74–86. (In Russ.)]. https://doi.org/10.26269/mxvp-ny43
  7. Kolkhir P., Church M.K., Weller K., et al. Autoimmune chronic spontaneous urticaria: What we know and what we do not know. J Allergy Clin Immunol. 2017;139(6):1772-1781. https://doi.org/10.1016/j.jaci.2016.08.050
  8. Шкодкина С.А., Афонина И.А. Хроническая спонтанная крапивница: особенности иммунопатогенеза и новые подходы к лечению. Актуальные проблемы медицины. 2025;48(1):5-14. [Shkodkina S.A., Afonina I.A. Chronic spontaneous urticaria: features of immunopathogenesis and new approaches to treatment. Aktual’nye problemy mediciny. 2025;48(1):5-14. (In Russ.)]. https://doi.org/10.52575/2687-0940-2025-48-1-5-14
  9. Bracken S.J., Abraham S., MacLeod A.S. Autoimmune Theories of Chronic Spontaneous Urticaria. Front Immunol. 2019;10:627. https://doi.org/10.3389/fimmu.2019.00627
  10. Maurer M., Altrichter S., Schmetzer O., et al. Immunoglobulin EMediated Autoimmunity. Front Immunol. 2018;9:689. https://doi.org/10.3389/fimmu.2018.00689
  11. Переверзина Н.О., Круглова Л.С., Мусаев И.Э. Настоящее и будущее в терапии хронической спонтанной крапивницы. Клиническая дерматология и венерология. 2020;19(5):604–612. [Pereverzina NO, Kruglova LS, Musaev IE. Present and future in the treatment of chronic spontaneous urticaria. Russian Journal of Clinical Dermatology and Venereology. 2020;19(5):604 612.(In Russ.)] ttps://doi.org/10.17116/klinderma202019051604
  12. Larenas-Linnemann D. Biomarkers of Autoimmune Chronic Spontaneous Urticaria. Curr Allergy Asthma Rep. 2023;23(12):655-664. https://doi.org/10.1007/s11882-023-01117-7
  13. Орлова Е.А., Кандрашкина Ю.А., Костина Е.М. Современный взгляд на вопросы диагностики и лечения хронической крапивницы. Практическая аллергология. 2025;2:32–38. [Orlova E.A., Kandrashkina Yu.A., Kostina E.M. Modern view on the issues of diagnosis and treatment of chronic urticaria. Prakticheskaya allergologiya. 2025;2:32–38. (In Russ.)]. https://doi.org/10.46393/27129667_2025_2_32–38
  14. Maurer M., Giménez-Arnau A., Ensina L.F., et al. Chronic urticaria treatment patterns and changes in quality of life: AWARE study 2-year results. The World Allergy Organization journal. 2020;13(9):100460. https://doi.org/10.1016/j.waojou.2020.100460
  15. Фомина Д.С., Мальцева Н.П., Сердотецкова С.А. и др. Эпидемиология хронических индуцированных крапивниц в городе Москве. Российский аллергологический журнал. 2022;19(3):317–327. [Fomina D.S., Mal’ceva N.P., Serdoteckova S.A., et al. Epidemiology of chronic induced urticaria in the city of Moscow. Rossijskij allergologicheskij zhurnal. 2022;19(3):317–327. (In Russ.)]. https://doi.org/10.36691/RJA1573
  16. Kulthanan K., Church M.K., Grekowitz E.M., et al. Evidence for histamine release in chronic inducible urticariaa systematic review. Front Immunol. 2022;13:901851. https://doi.org/10.3389/fimmu.2022.901851
  17. Maurer M., Hawro T., Krause K., et al. Diagnosis and treatment of chronic inducible urticaria. Allergy. 2019;74(12):2550–2553. https://doi.org/10.1111/all.13878
  18. Sánchez J., Amaya E., Acevedo A., et al. Prevalence of Inducible Urticaria in Patients with Chronic Spontaneous Urticaria: Associated Risk Factors. The journal of allergy and clinical immunology. In practice. 2017;5(2):464–470. https://doi.org/10.1016/j.jaip.2016.09.029
  19. Saini S., Shams M., Bernstein J.A., Maurer M. Urticaria and Angioedema Across the Ages. The journal of allergy and clinical immunology. In practice. 2020;8(6):1866–1874. https://doi.org/10.1016/j.jaip.2020.03.030
  20. Скандер Д.М., Алленова А.С., Самсонян М.Л., Колхир П.В. Эффективность омализумаба у больных хронической спонтанной крапивницей в сочетании с несколькими формами индуцированной крапивницы. Медицинский алфавит. 2019;2(21):5–8. [Skander D.M., Allenova A.S., Samsonyan M.L., Kolhir P.V. Efficacy of omalizumab in patients with chronic spontaneous urticaria in combination with several forms of induced urticaria. Medicinskij alfavit. 2019;2(21):5–8. (In Russ.)]. https://doi.org/10.33667/2078-5631-2019-2-21(396)-5-8
  21. Сердотецкова С.А., Данилычева И.В., Фомина Д.С. и др. Хроническая индуцированная крапивница: классификация, современные аспекты диагностики и терапии. Российский аллергологический журнал. 2023;20(1):74–96. [Serdoteckova S.A., Danilycheva I.V., Fomina D.S., et al. Chronic induced urticaria: classification, modern aspects of diagnosis and therapy. Rossijskij allergologicheskij zhurnal. 2023;20(1):74–96. (In Russ.)]. https://doi.org/10.36691/RJA1925
  22. Awosika O., Qureshi A., Ehrlich A., Fonacier L. «Chronic Urticaria»: Recommendations From an Allergist and Immunologist. Dermatitis: contact, atopic, occupational, drug. 2018;29(5):292–293. https://doi.org/10.1097/DER.0000000000000384
  23. Zuberbier T., Abdul Latiff A.H., Abuzakouk M., et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2020;77(3):734–766. https://doi.org/10.1111/all.15090
  24. Giménez-Arnau A.M., Jáuregui I., Silvestre-Salvador J.F., et al. Consensus on the Definition of Control and Remission in Chronic Urticaria. Journal of investigational allergology & clinical immunology. 2022;32(4):261–269. https://doi.org/10.18176/jiaci.0820
  25. Василюк В.Б., Фарапонова М.В., Верведа А.Б. и др. Исследование фармакокинетики и биоэквивалентности препарата Аллергостин в сравнении с препаратом Кестин при однократном приеме у здоровых добровольцев. Российский аллергологический журнал. 2023;20(2):143–151. [Vasilyuk V.B., Faraponova M.V., Verveda A.B., et al. Study of pharmacokinetics and bioequivalence of Allergostin in comparison with Kestin after a single dose in healthy volunteers. Rossijskij allergologicheskij zhurnal. 2023;20(2):143–151. (In Russ.)]. https://doi.org/10.36691/RJA7525
  26. Saito J., Yakuwa N., Sandaiji N., et al. Ebastine during pregnancy and lactation in a patient with chronic urticaria: ebastine and carebastine levels in maternal serum, cord blood, breast milk and the infant’s serum. Journal of the European Academy of Dermatology and Venereology: JEADV, 2020;34(9):e496–e497. https://doi.org/10.1111/jdv.1641527.
  27. Vincent J., Liminana R., Meredith P.A., Reid J.L. The pharmacokinetics, antihistamine and concentration-effect relationship of ebastine in healthy subjects. British journal of clinical pharmacology. 1988;26(5):497–502. https://doi.org/10.1111/j.1365-2125.1988.tb05288.x
  28. Kang W., Liu K.H., Ryu J. Y., Shin J.G. Simultaneous determination of ebastine and its three metabolites in plasma using liquid chromatography-tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2004;813(1-2):75–80. https://doi.org/10.1016/j.jchromb.2004.09.017
  29. Овчинников А.Ю., Мирошниченко Н.А., Симсова В.А. Эбастин в лечении больных аллергическим ринитом. Медицинский совет. 2019;12:58-62. [Ovchinnikov A.Yu., Miroshnichenko N.A., Simsova V.A. Ebastine in the treatment of patients with allergic rhinitis. Medicinskij sovet. 2019;12:58-62. (In Russ.)]. https://doi.org/10.21518/2079-701X-2019-12-58-62
  30. Ивкин Д.Ю., Гришина А.Ю., Петрова А.Г. и др. Преимущества эбастина с позиций клинической фармакологии. Лечащий врач. 2023;4(26):7-16. [Ivkin D.Yu., Grishina A.Yu., Petrova A.G., et al. Advantages of ebastine from the standpoint of clinical pharmacology. Lechashchij Vrach. 2023;4(26):7-16.
  31. Быкова Г.А., Наумова В.В., Царегородцева А.А., Бельтюков Е.К. Клиническое наблюдение пациентов с сочетанным течением хронической спонтанной и индуцированной крапивницы. Медицинский совет. 2025;19(20):130–136. [Bykova G.A., Naumova V.V., Tsaregorodtsev A.A., Beltyukov E.К. Clinical cases of patients with combined course of chronic spontaneous and induced urticaria. Meditsinskiy sovet = Medical Council. 2025;(20):130-136. (In Russ.)]. https://doi.org/10.21518/ms2025-397

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2026 Bionika Media

License URL: https://journals.eco-vector.com/2073-4034/about/editorialPolicies